The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
Adele surprised a fan with an accidental kiss on the lips when as she said hello at a show in Vancouver, Canada.
Hot sunshine and thundery downpours in places
Two people have been pulled from the sea and are being treated by paramedics on an East Anglian beach.